Retour
54
Fourchette du Jour
1,65 €
1,77 €
Fourchette 52 Semaines
0,32 €
1,83 €
Volume
2 707 398
Moyenne 50J / 200J
1,45 €
/
1,26 €
Clôture Précédente
1,72 €
Quick Summary
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (627 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -14,1 | 0,3 |
| P/B | 6,6 | 3,0 |
| ROE % | -39,7 | 3,7 |
| Net Margin % | -101,1 | 3,8 |
| Rev Growth 5Y % | 259,6 | 10,0 |
| D/E | 0,6 | 0,2 |
Objectif de Cours des Analystes
Hold
6,00 €
+257.1%
BPA Prévisionnel
-0,18 €
CA Est.
33,92M
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2030 |
0,06 €
0,05 € – 0,07 €
|
157,63M | 2 |
| FY2029 |
0,01 €
0,01 € – 0,01 €
|
125,46M | 2 |
| FY2028 |
-0,11 €
-0,18 € – 0,02 €
|
68,76M | 4 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2026-03-05 | -0,07 € | -0,04 € | +42,9% |
| 2025-11-06 | -0,07 € | -0,04 € | +42,9% |
| 2025-08-06 | -0,08 € | 0,01 € | +112,5% |
| 2025-05-13 | -0,10 € | -0,07 € | +30,0% |
| 2025-03-06 | -0,11 € | -0,09 € | +18,2% |
| 2024-11-12 | -0,17 € | -0,18 € | -5,9% |
| 2024-08-01 | -0,18 € | -0,17 € | +5,6% |
| 2024-05-02 | -0,18 € | -0,20 € | -11,1% |
Insider Trading Activity
Buy ratio (90d)
100.0%
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 28, 2026 |
Gopinathan Suma
SVP, Discovery
|
other | 224 238 | — | — |
| Feb 28, 2026 |
Granowitz Craig B
SVP, Chief Medical Officer
|
other | 733 650 | — | — |
| Feb 28, 2026 |
McDermott Wendy
SVP, Human Resources
|
other | 516 919 | — | — |
| Feb 23, 2026 |
DEBBANE RAYMOND
Director
|
buy | 100 000 | 1,47 € | 147 000,00 € |
| Feb 12, 2026 |
Crum Brian T
SVP, General Counsel & Secr.
|
grant | 749 270 | — | — |
| Feb 12, 2026 |
Granowitz Craig B
SVP, Chief Medical Officer
|
grant | 866 530 | — | — |
| Feb 12, 2026 |
Exton Michael
Chief Executive Officer
|
grant | 2 156 110 | — | — |
| Feb 12, 2026 |
Coiante Scott M
SVP, Chief Financial Officer
|
grant | 681 700 | — | — |
| Feb 12, 2026 |
Gopinathan Suma
SVP, Discovery
|
grant | 596 130 | — | — |
| Feb 12, 2026 |
McDermott Wendy
SVP, Human Resources
|
grant | 625 500 | — | — |
| Feb 12, 2026 |
DeFrancesco Lisa
SVP, IR and Corp Comm
|
grant | 643 830 | — | — |
| Jun 3, 2025 |
DEBBANE RAYMOND
Director
|
grant | 193 118 | — | — |
| Jun 3, 2025 |
Amouyal Philippe
Director
|
grant | 193 118 | — | — |
| Jun 3, 2025 |
Cheung Ivan
Director
|
grant | 193 118 | — | — |
| Jun 3, 2025 |
BARKER SAM L
Director
|
grant | 193 118 | — | — |
| Jun 3, 2025 |
SOBECKI CHRISTOPHER J
Director
|
grant | 193 118 | — | — |
| May 13, 2025 |
Swain Judith L
Director
|
other | 73 620 | — | — |
| May 13, 2025 |
Amouyal Philippe
Director
|
other | 73 620 | — | — |
| May 13, 2025 |
BARKER SAM L
Director
|
other | 73 620 | — | — |
| May 13, 2025 |
Sullivan Diane E.
Director
|
other | 73 620 | — | — |
Dividend History
Yield
0,00%
Payout Ratio
0,00%
Growth (3Y)
N/A
Growth (5Y)
N/A
No dividend history available.
Points Clés
Revenue grew 259,55% annually over 5 years — strong growth
Negative free cash flow of -67,85M
PEG of 0,11 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 199,31%
Capital efficient — spends only 0,00% of revenue on capex
Croissance
Revenue Growth (5Y)
259,55%
Revenue (1Y)60,24%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-39,72%
ROIC-21,61%
Net Margin-101,08%
Op. Margin-98,21%
Sécurité
Debt / Equity
0,58
Current Ratio4,88
Interest Coverage-5,87
Valorisation
P/E Ratio
-14,14
Forward P/EN/A
P/B Ratio6,62
EV/EBITDAN/A
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 60,24% | Revenue Growth (3Y) | 543,15% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 259,55% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 49,80M | Net Income (TTM) | -50,34M |
| ROE | -39,72% | ROA | -27,21% |
| Gross Margin | 99,45% | Operating Margin | -98,21% |
| Net Margin | -101,08% | Free Cash Flow (TTM) | -67,85M |
| ROIC | -21,61% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,58 | Current Ratio | 4,88 |
| Interest Coverage | -5,87 | ||
| Dividends | |||
| Dividend Yield | 0,00% | Payout Ratio | 0,00% |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -14,14 | Forward P/E | N/A |
| P/B Ratio | 6,62 | P/S Ratio | 14,29 |
| PEG Ratio | 0,11 | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 20,98 | Fwd Earnings Yield | N/A |
| FCF Yield | -9,53% | ||
| Market Cap | 711,78M | Enterprise Value | 739,69M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 49,80M | 31,08M | 1,20M | 139 000,0 | 298 000,0 |
| Net Income | -50,34M | -200,40M | -177,12M | -101,94M | -87,76M |
| EPS (Diluted) | -0,14 | -0,63 | -0,80 | -0,62 | -0,61 |
| Gross Profit | 49,53M | 30,47M | -57,77M | -52,38M | -54,75M |
| Operating Income | -48,91M | -197,12M | -171,75M | -100,76M | -87,09M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 184,99M | 298,42M | 229,43M | 194,30M | 136,91M |
| Total Liabilities | 77,45M | 152,47M | 136,32M | 77,18M | 23,31M |
| Shareholders' Equity | 107,54M | 145,95M | 93,11M | 117,12M | 113,60M |
| Total Debt | 62,24M | 108,40M | 106,06M | 55,29M | 2,28M |
| Cash & Equivalents | 34,33M | 66,66M | 22,47M | 46,35M | 64,07M |
| Current Assets | 101,90M | 246,19M | 176,55M | 140,87M | 88,92M |
| Current Liabilities | 20,87M | 45,25M | 31,55M | 23,17M | 22,12M |
Scores de Stratégies
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Full Throttle
#47 of 146
Activité Récente
Entré
Full Throttle
Mar 24, 2026